Esperion Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
3analysts covering
FY EPS (est.)
-$0.21next fiscal year
Monitoring Framework
Key Performance Indicators
U.S. Net Product Sales of Bempedoic Acid Franchise (Nexletol and Nexlizet) Annually158M
Annual Operating Expenses AnnuallyTarget: 225000000 to 255000000
Watch Items
- Stockholder Approval of ARCHIMED Merger AgreementTrigger: Majority vote of outstanding shares at the Special MeetingAction: Vote scheduled for July 8, 2026; if approved, proceed to transaction closing in Q3 2026
- U.S. Annual Net Sales of Bempedoic Acid-Containing Products in 2027Trigger: Exceeding $350,000,000Action: Triggers full $40,000,000 payout under the first tranche of the Contingent Value Right (CVR)
- U.S. Annual Net Sales of Bumetanide-Containing Products (Enbumyst)Trigger: Exceeding $160,000,000 in any single calendar year through December 31, 2030Action: Triggers $60,000,000 payout under the second tranche of the Contingent Value Right (CVR)
Research as of 19 Jun 2026